Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant cause » significant change (Expand Search), significant changes (Expand Search), significant increase (Expand Search)
Showing 461 - 480 results of 21,342 for search '(( ((significant gap) OR (significant cause)) decrease ) OR ( significant decrease decrease ))', query time: 0.39s Refine Results
  1. 461
    PRISMA flowchart of the study selection process.

    PRISMA flowchart of the study selection process. by Yohannis Derbew Molla (16471771)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 462
    Fer-1 alleviated liver lesions caused by <i>C. sinensis.</i>

    Fer-1 alleviated liver lesions caused by <i>C. sinensis.</i> by Haoyang Zhang (1706815)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 463
    Inhibition of ferroptosis alleviated liver fibrosis caused by <i>C. sinensis.</i>

    Inhibition of ferroptosis alleviated liver fibrosis caused by <i>C. sinensis.</i> by Haoyang Zhang (1706815)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 464
    ALKG1202R –ABT199 interactions.

    ALKG1202R –ABT199 interactions. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 465
    ALKC1156Y –ABT199 interactions.

    ALKC1156Y –ABT199 interactions. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 466
    S1 Data -

    S1 Data - by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 467
    Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models.

    Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 468
    Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.

    Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 469
    Molecular docking showed that ABT-199 can fit into active site of ALK<sup>Mutant</sup>.

    Molecular docking showed that ABT-199 can fit into active site of ALK<sup>Mutant</sup>. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 470
    The binding energy values of ATP, ALK inhibitors and ABT-199 to ALK were obtained from AlphaFold and modeled protein structures.

    The binding energy values of ATP, ALK inhibitors and ABT-199 to ALK were obtained from AlphaFold and modeled protein structures. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 471
    Amino acids interactions and binding energy describe that ABT-199 binds to ALK<sup>Mutant</sup>.

    Amino acids interactions and binding energy describe that ABT-199 binds to ALK<sup>Mutant</sup>. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 472
    Western blot analysis of drug combinations.

    Western blot analysis of drug combinations. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 473
    ALKL1196M –ABT199 interactions.

    ALKL1196M –ABT199 interactions. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 474
    ALK<sup>wt</sup>–ABT199 interactions.

    ALK<sup>wt</sup>–ABT199 interactions. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 475
    BCL2 protein keeps their expression in different conditions treatment nevertheless each EML4-ALK cell modells exhibit variable expression.

    BCL2 protein keeps their expression in different conditions treatment nevertheless each EML4-ALK cell modells exhibit variable expression. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 476
    ALK inhibitors (Positive control) and ABT199 (Proposed binding) in complex with the ALK active side.

    ALK inhibitors (Positive control) and ABT199 (Proposed binding) in complex with the ALK active side. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 477
    BCL2 antiapoptotic protein exhibits heterogeneous expression in Ba/F3 EML4-ALK<sup>mutants</sup>.

    BCL2 antiapoptotic protein exhibits heterogeneous expression in Ba/F3 EML4-ALK<sup>mutants</sup>. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 478
    Loewe synergy-antagonism score analysis shows additive and synergistic effects after ALKi and ABT-199 combination treatment.

    Loewe synergy-antagonism score analysis shows additive and synergistic effects after ALKi and ABT-199 combination treatment. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 479
    Negative (Prednisone) and basal (ATP) control compounds binding to ALK protein.

    Negative (Prednisone) and basal (ATP) control compounds binding to ALK protein. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 480
    Scatter plots of the relationships between age and the proportions of cells which statistically significantly correlated with age.

    Scatter plots of the relationships between age and the proportions of cells which statistically significantly correlated with age. by Arttu Autio-Kimura (20454681)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: